Percutaneous transluminal coronary angioplasty · overweight or obese adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · overweight or obese adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse eventsMeasurement unclear · overweight or obese adults
1 finding from 1 review
Total and cardiovascular mortality · Adults with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatal or nonfatal myocardial infarction · Adults with coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Deep vein thrombosis · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin probably leads to lower deep venous thrombosis compared with no prophylaxis or placebo (moderate certainty).
1 finding from 1 review
Pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in pulmonary embolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Symptomatic venous thromboembolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin may leads to lower symptomatic venous thromboembolism compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Mortality due to pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
1 finding from 1 review
Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Adverse outcomes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in adverse outcomes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Myocardial infarction · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in myocardial infarction compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Stroke · people with or without existing cardiovascular disease, men and women
It is very uncertain whether homocysteine‐lowering interventions (high dose) changes stroke compared with homocysteine‐lowering interventions (low dose) (very low certainty).
1 finding from 1 review
Death by any cause · people with or without existing cardiovascular disease, men and women
Homocysteine‐lowering interventions (high dose) showed no clear difference in death by any cause compared with homocysteine‐lowering interventions (low dose) (moderate certainty).
1 finding from 1 review
Cancer · people with or without existing cardiovascular disease, men and women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · infants with bronchiolitis
1 finding from 1 review
Adverse events · infants with bronchiolitis
Summary of findings table ‐ High‐flow nasal cannula showed no clear difference in adverse events compared with standard oxygen therapy (low‐flow) (low certainty).
1 finding from 1 review
Change in respiratory rate at 20 minutes · infants with bronchiolitis
1 finding from 1 review
Change** in heart rate (beats/min) · infants with bronchiolitis
1 finding from 1 review
Need for treatment escalation · infants with bronchiolitis
Summary of findings table ‐ High‐flow nasal cannula probably leads to lower need for treatment escalation compared with standard oxygen therapy (low‐flow) (moderate certainty).
1 finding from 1 review